Table 3.

Association of covariates with mean eGFR change per year among patients with SCT and patients with SCD

CovariatesSCT β (95% CI), ml/min per 1.73 m2 per yrSCD β (95% CI), ml/min per 1.73 m2 per yr
Men−1.47 (−1.58 to −1.37)−0.24 (−0.41 to −0.08)
Hypertension−1.21 (−1.31 to −1.11)−0.13 (−0.36 to 0.09)
DM−1.62 (−1.72 to −1.52)−2.76 (−3.07 to −2.45)
CVD−0.75 (−0.85 to −0.64)−0.38 (−0.55 to −0.22)
ACEi/ARB use−1.39 (−1.49 to −1.29)−2.34 (−2.52 to −2.16)
Aspirin use−1.19 (−1.29 to −1.09)−1.11 (−1.29 to −0.93)
Statin use−1.45 (−1.54 to −1.35)−1.13 (−1.31 to −0.95)
Hemoglobin0.36 (0.34 to 0.39)0.34 (0.30 to 0.38)
Leukocyte count−0.07 (−0.09 to −0.06)0.04 (0.03 to 0.06)
Low HbS (<35%)−0.57 (−0.68 to −0.46)
Low HbS (<35%) adjusting for MCV−0.51 (−0.64 to −0.37)
HbS (versus 19%–34.8%)
 34.9%–38.9%0.67 (0.55 to 0.80)
 39%–47.2%0.49 (0.36 to 0.61)
Elevated HbF (>0.4%)1.05 (0.92 to 1.18)
Elevated HbA (>70%)−1.92 (−2.11 to −1.74)
Elevated HbA2 (>3.5%)0.84 (0.73 to 0.95)
Hydroxyurea−1.17 (−1.38 to −0.95)
Hospital visits/year for crises (versus <1/yr)
 1–2 per yr−2.06 (−2.42 to −1.71)
 >2 per yr−2.92 (−3.17 to −2.66)
  • eGFR obtained using CKD-EPI creatinine equation. All coefficients were adjusted for baseline age, sex, hypertension, DM, history of CVD, AKI during follow-up, smoking status, ACEi/ARB use, urine ACR categories, and baseline eGFR. Hemoglobin electrophoresis indication was included in SCT models. Hemoglobin phenotype models were adjusted for all phenotypes. Hydroxyurea was included in SCD models. MCV, mean corpuscular volume.